Marinus Pharmaceuticals(MRNS)
搜索文档
Marinus Pharmaceuticals(MRNS) - 2023 Q2 - Earnings Call Presentation
2023-08-10 20:01
Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation August 2023 ...
Marinus Pharmaceuticals(MRNS) - 2023 Q2 - Quarterly Report
2023-08-10 19:55
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-36576 MARINUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 20-0198082 (State or o ...
Marinus Pharmaceuticals(MRNS) - 2023 Q1 - Quarterly Report
2023-05-11 20:01
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-36576 MARINUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 20-0198082 (State or ...
Marinus Pharmaceuticals(MRNS) - 2022 Q4 - Annual Report
2023-03-10 05:03
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36576 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0198082 (State or other ju ...